Affimed NV
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, … Read more
Affimed NV - Asset Resilience Ratio
Affimed NV (AFMD) has an Asset Resilience Ratio of 43.88% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2023)
This chart shows how Affimed NV's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Affimed NV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $17.54 Million | 43.88% |
| Total Liquid Assets | $17.54 Million | 43.88% |
Asset Resilience Insights
- Very High Liquidity: Affimed NV maintains exceptional liquid asset reserves at 43.88% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Affimed NV Industry Peers by Asset Resilience Ratio
Compare Affimed NV's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Affimed NV (2014–2023)
The table below shows the annual Asset Resilience Ratio data for Affimed NV.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 35.37% | $34.37 Million | $97.16 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $200.51 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $175.72 Million | -- |
| 2019-12-31 | 7.92% | $8.90 Million | $112.36 Million | -4.11pp |
| 2018-12-31 | 12.03% | $13.97 Million | $116.17 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $43.16 Million | -- |
| 2016-12-31 | 19.46% | $9.49 Million | $48.74 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $79.32 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $41.91 Million | -- |